On August 19th, 2022, Emerald Health Therapeutics shareholders voted in favour of the Plan of Arrangement previously announced on May 12, 2022, for Skye Bioscience (OTCQB: SKYE) to acquire all issued and outstanding shares of Emerald Health Therapeutics. Subsequently, on September 30, 2022, Skye shareholders voted in favour of the Plan of Arrangement. Skye is a San Diego-based pharmaceutical company developing proprietary, synthetic cannabinoid derivatives to treat glaucoma and other diseases with significant unmet needs.
Skye and EHT continue to work diligently towards closing the Arrangement and plan to proceed with the closing as soon as practicable following the satisfaction of all remaining closing conditions, including obtaining conditional listing approval from the Canadian Securities Exchange.
We encourage you to learn more about Skye by exploring its website and staying up-to-date via its corporate newsletter and social channels. Follow the links below!
On November 10, 2022, Emerald Health Therapeutics, Inc. was acquired by Skye Bioscience, Inc. (OTCQB:SKYE), a San Diego-based pharmaceutical company developing proprietary, synthetic cannabinoid derivatives to treat glaucoma and other diseases with significant unmet needs. Skye is currently conducting Phase 1 clinical trial for its lead candidate SBI-100 Ophthalmic Emulsion and expects to initiate its Phase 2 study shortly. We are also conducting research to expand our pipeline of potential drug candidates.
Learn about Skye by exploring its website and staying up-to-date via its corporate newsletter and social channels. Follow the links below!
No scheduled events at this time.
Currency in CAD. Stock chart updated daily.
Emerald’s operational facilities are designed to provide defined-scale, high quality dried flower to the premium market segment and to support the development of differentiated specialty cannabis products.
Mr. Mosgrove has over 15 years of sales and marketing leadership experience in commercial plan development and implementation, building top brands, and improving supply chain efficiencies in the Canadian alcohol beverage and cannabis sectors. He has led sales teams that enhanced revenue growth, gross margins and profitability, and key account satisfaction. Most recently, Mr. Mosgrove served as VP Sales & Marketing for TerrAscend Canada. Prior to this he held provincial sales manager roles in Ontario with Campari Canada, Escalade Wines & Spirits, Select Wine & Spirits and Bacardi Canada.
Mr. Jiwan is a data driven business leader with over 20 years experience in strategic development , sales and operations management , e-commerce, and developing data and business intelligence solutions. Before joining Emerald, he served in senior leadership positions, including Chief Information Officer and Chief Customer Officer, for established cannabis and healthcare companies, including senior roles at TerrAscend Corp and Shopper’s Drug Mart. With a strong marketing and customer orientation, he has strongly focused on operational excellence and implementing processes to function faster, smarter, and leaner.
Ms. Wong has over 30 years of quality and regulatory management experience in pharmaceutical and life science companies regulated to Canadian, US, European and international requirements. She has been responsible for establishing quality systems and ensuring regulatory compliance through all phases of product development from GPP, GLP, GCP, GMP for cannabis, pharmaceuticals, medical devices, combination products and biologicals. She was previously Executive Director of Quality Assurance at Novelion Therapeutics (formerly QLT Inc.) and worked for life science companies including MDS Nordion, Cangene Corporation, and Biomira Inc. Ms. Wong earned a B.Sc. (Microbiology) from the University of Alberta.
Ms. Hepburn has over a decade of experience in accounting and finance and is an experienced manager of privately and publicly traded manufacturing and mining businesses operating in Canada and the USA. Prior to joining Emerald, Ms. Hepburn was the Director of Finance and Administration at bioLytical Laboratories Inc., a medical diagnostics manufacturer. Before that, she held controller positions at junior gold and silver mining companies Northern Vertex Mining Corp., Kootenay Silver Inc. and Theia Resources Ltd. Ms. Hepburn earned a BBA from Simon Fraser University and her certification from the Certified Management Accountants of British Columbia.
Mr. Bandali’s expertise in global operations, strategy development, driving innovation, M&A, and investment management has been developed over a 25-year career in the life sciences sector spanning contract clinical and research services, analytical instrumentation, lab services and venture capital.
He holds an Advanced Management Program Degree from Harvard Business School, a Master of Business Administration from McGill University, and a Bachelor of Science from the University of British Columbia. He is an innovative business leader who has built strategic and operating plans that have resulted in rapid growth and significant profitability enhancement. He has managed businesses and operations with a global footprint and has led teams of over 900 people.
Mr. Bandali’s previous experience includes serving as President, Early Phase Clinical Services and Translational Science, Syneos Health; President, Early Stage Development, as well as Chief Innovation Officer, inVentiv Health Clinical; Senior Vice President, Strategy and Business Development, AB Sciex and Molecular Devices (part of Danaher Corporation); Senior Vice President, Strategy, Legal and Corporate Development, MDS Analytical Technologies; and Vice President and General Manager, Global Early Stage Development, MDS Pharma Services. He was also Venture Partner and Vice President at MDS Capital and has served on the boards of private and public companies.